Ansab, M., Rath, S., Lal, A. (2026). Afatinib versus chemotherapy in advanced NSCLC with uncommon
                    <i>EGFR</i>
                    mutations: A pooled individual patient–level survival analysis of ACHILLES/TORG1834 and LUX-Lung 2/3/6.. Journal of Clinical Oncology. https://doi.org/10.1200/jco.2026.44.16_suppl.e20736